Showing results (811-820 of 1,396) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|February 28, 2025
Challenging Conventional Diagnostic Methods by Comprehensive Molecular Diagnostics: A Nationwide Prospective Comparison in Children With ALLJudith M Boer, Marco J Koudijs, Lennart A Kester, et al.
JCO Precision Oncology|August 8, 2024
Genomic Profiling of Small Intestine Cancers From a Real-World Data Set Identifies Subgroups With Actionable AlterationsHiroyuki Takeda, Hiroyuki Yamamoto, Ritsuko Oikawa, et al.
JCO Precision Oncology|August 5, 2024
Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung CancerHuaying Wang, Lie Lin, Chuqiao Liang, et al.
JCO Precision Oncology|August 5, 2024
Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract CancersThejus Jayakrishnan, Yasmine Baca, Joanne Xiu, et al.
JCO Precision Oncology|August 1, 2024
Germline Susceptibility to Renal Cell Carcinoma and Implications for Genetic ScreeningKate I Glennon, Mikiko Endo, Yoshiaki Usui, et al.
JCO Precision Oncology|June 21, 2024
Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate CancerDaniel Ang, Johan Chan, Whee Sze Ong, et al.
JCO Precision Oncology|January 23, 2023
Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World DataCarsten Bokemeyer, Noman Paracha, Ulrik Lassen, et al.
JCO Precision Oncology|July 12, 2021
Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket StudyLillian M Smyth, Jonathan B Reichel, Jiabin Tang, et al.
JCO Precision Oncology|July 12, 2021
Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of HealthP Mickey Williams, Thomas Forbes, Steven P Lund, et al.
JCO Precision Oncology|April 23, 2019
Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-HighSumit Middha, Rona Yaeger, Jinru Shia, et al.
Pageof 140